Cellectis (NASDAQ:CLLS) Upgraded by StockNews.com to Hold

StockNews.com upgraded shares of Cellectis (NASDAQ:CLLSGet Rating) from a sell rating to a hold rating in a research note published on Thursday.

Several other research firms have also recently issued reports on CLLS. Zacks Investment Research cut Cellectis from a hold rating to a sell rating in a research note on Thursday, January 6th. Wells Fargo & Company lowered shares of Cellectis from an overweight rating to an equal weight rating and reduced their price objective for the company from $39.00 to $16.00 in a report on Thursday, January 6th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of Hold and an average target price of $21.00.

Shares of CLLS opened at $3.64 on Thursday. Cellectis has a 52-week low of $3.43 and a 52-week high of $19.68. The company has a quick ratio of 4.57, a current ratio of 4.57 and a debt-to-equity ratio of 0.08. The stock has a fifty day simple moving average of $4.23 and a two-hundred day simple moving average of $6.96. The company has a market capitalization of $165.59 million, a PE ratio of -1.44 and a beta of 2.25.

Cellectis (NASDAQ:CLLSGet Rating) last released its quarterly earnings data on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.05) by $0.50. Cellectis had a negative net margin of 170.26% and a negative return on equity of 41.88%. The firm had revenue of $13.66 million during the quarter, compared to analysts’ expectations of $12.30 million. During the same period last year, the business earned ($0.95) earnings per share. As a group, equities analysts anticipate that Cellectis will post -2.37 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Moors & Cabot Inc. acquired a new position in Cellectis in the 3rd quarter valued at about $287,000. US Bancorp DE grew its holdings in shares of Cellectis by 94.0% in the third quarter. US Bancorp DE now owns 2,332 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,130 shares in the last quarter. Deutsche Bank AG purchased a new stake in Cellectis during the 3rd quarter worth approximately $42,000. Signaturefd LLC increased its stake in Cellectis by 1,066.0% during the 4th quarter. Signaturefd LLC now owns 3,801 shares of the biotechnology company’s stock worth $31,000 after buying an additional 3,475 shares during the period. Finally, Advisor Group Holdings Inc. lifted its holdings in Cellectis by 73.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 4,950 shares of the biotechnology company’s stock worth $40,000 after buying an additional 2,103 shares in the last quarter. 39.04% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectis (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

See Also

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.